CD8A and neoplasm: DR-18 exerted potent antitumor effects in mouse models of melanoma and colon cancer by remodeling the immune tumor microenvironment (TME) and activating antigen-specific CD8+ tumor-infiltrating lymphocytes (TILs), which were sufficient to induce antitumor responses.